Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression

NCT02285504 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02285504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2015
Completion date
June 5, 2015
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postpartum depression